Adage Capital Partners Gp, L.L.C. Madrigal Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $59.7 Billion
- Q3 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 88,500 shares of MDGL stock, worth $46.8 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
88,500
Previous 376,163
76.47%
Holding current value
$46.8 Million
Previous $114 Million
64.34%
% of portfolio
0.07%
Previous 0.2%
Shares
23 transactions
Others Institutions Holding MDGL
# of Institutions
391Shares Held
23.2MCall Options Held
654KPut Options Held
490K-
Baker Bros. Advisors LP New York, NY2.14MShares$1.13 Billion8.0% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$1.06 Billion12.22% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.91MShares$1.01 Billion31.28% of portfolio
-
Janus Henderson Group PLC London, X01.84MShares$975 Million0.41% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.83MShares$970 Million11.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $9.05B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...